AMGN
Amgen Inc.
Revenue by product
2025, ended Dec 31, 2025
Earlier:
Products by fiscal year
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product sales | 35.1B | 32.0B | 26.9B | 24.8B | — | — | 22.2B | — | — | — | — | — | — | — | — | — | — |
Other products | 7.26B | 5.63B | 4.70B | 5.05B | 5.71B | 5.37B | 4.74B | 5.57B | 2.58B | 3.16B | — | — | — | — | — | — | — |
Repatha | 3.02B | 2.22B | 1.64B | 1.30B | 1.12B | 0.89B | 0.66B | 0.55B | — | — | — | — | — | — | — | — | — |
Evenity | 2.10B | 1.56B | 1.16B | 0.79B | 0.53B | 0.35B | — | — | — | — | — | — | — | — | — | — | — |
Prolia | 4.41B | 4.37B | 4.05B | 3.63B | 3.25B | 2.76B | 2.67B | 2.29B | 1.97B | 1.64B | — | — | — | — | 0.20B | — | — |
Enbrel | 2.23B | 3.32B | 3.70B | 4.12B | 4.47B | 5.00B | 5.23B | 5.01B | 5.43B | 5.97B | — | — | — | — | 3.70B | — | 3.49B |
Tezspire | 1.48B | 0.97B | 0.57B | 0.17B | — | — | — | — | — | — | — | — | — | — | — | — | — |
Tepezza | 1.90B | 1.85B | 0.45B | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Blincyto | 1.56B | 1.22B | 0.86B | 0.58B | 0.47B | — | — | — | — | — | — | — | — | — | — | — | — |
Otezla | 2.27B | 2.13B | 2.19B | 2.29B | 2.25B | 2.20B | 0.18B | — | — | — | — | — | — | — | — | — | — |
Nplate | 1.52B | 1.46B | 1.48B | 1.31B | 1.03B | 0.85B | 0.80B | — | — | — | — | — | — | — | 0.30B | — | 0.11B |
Krystexxa | 1.34B | 1.19B | 0.27B | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Vectibix | 1.18B | 1.05B | 0.98B | 0.89B | 0.87B | — | — | — | — | — | — | — | — | — | 0.32B | — | 0.23B |
Kyprolis | 1.41B | 1.50B | 1.40B | 1.25B | 1.11B | 1.07B | 1.04B | 0.97B | 0.84B | — | — | — | — | — | — | — | — |
Aranesp | 1.39B | 1.34B | 1.36B | 1.42B | 1.48B | 1.57B | 1.73B | 1.88B | 2.05B | 2.09B | — | — | — | — | 2.30B | — | 2.65B |
Xgeva | 2.08B | 2.23B | 2.11B | 2.01B | 2.02B | 1.90B | 1.94B | 1.79B | 1.58B | 1.53B | — | — | — | — | 0.35B | — | — |
Neulasta (pegfilgrastim) | — | — | — | — | — | 2.29B | 3.22B | 4.48B | 4.53B | 4.65B | — | — | — | — | 3.95B | — | 3.36B |
| Other revenues | 1.60B | 1.40B | 1.28B | 1.52B | 1.68B | 1.18B | 1.16B | 1.21B | 1.05B | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | 2.81B | 3.96B | — | — | — | — | 4.17B | — | 4.51B | |
| Sensipar / Mimpara (cinacalcet) | — | — | — | — | — | — | — | — | 1.72B | 1.58B | — | — | — | — | 0.81B | — | 0.22B |
| EPOGEN (epoetin alfa) | — | — | — | — | — | — | — | — | 1.10B | 1.28B | — | — | — | — | 2.04B | — | 2.57B |
| Other | — | — | — | — | — | — | — | — | — | 1.10B | — | — | — | — | 58M | — | — |
| Neupogen | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1.26B | — | 1.29B |
| Sensipar | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 429M |
| Total | 36.8B | 33.4B | 28.2B | 26.3B | 26.0B | 25.4B | 23.4B | 23.7B | 22.8B | 23.0B | 21.7B | 20.1B | 18.7B | 17.3B | 15.3B | 15.1B | 14.4B |
A period with only a total isn't split by product in the filings.